Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, taking place October 19-21, 2026, in Amsterdam, Netherlands. The presentation, scheduled for October 21 at 1:15 p.m. CEST, will address the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases. Tonix will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on October 20 at 11:30 a.m. CEST.
The announcement comes as mpox remains a global health concern, with outbreaks reported in various regions. TNX-801, if successful, could offer a new tool in the fight against mpox and potentially other infectious diseases. The World Vaccine Congress Europe is a significant platform for vaccine development, bringing together experts from around the world. Tonix's participation underscores its commitment to advancing immunology programs. For investors, this presentation could provide updates on the vaccine's progress and potential market opportunities. Tonix's pipeline also includes monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection, though these are investigational and not yet approved.
Tonix is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
For more information, the full press release can be viewed at https://ibn.fm/BHVjU. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
